AQST

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change +0.09
Percentage change 2.72	%

Peers: APLS XOMA BPMC CRSP ASND ACRS MGNX MDGL GLPG GERN

| Held by: IWM VTI VXF IWN VTWO IWO IWC ITOT RSSL GSSC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.58	Insider Own	7.70%	Shs Outstand	99.32M	Perf Week	5.92%
Market Cap	337.72M	Forward P/E	-	EPS next Y	-0.59	Insider Trans	0.00%	Shs Float	91.68M	Perf Month	25.46%
Enterprise Value	393.62M	PEG	-	EPS next Q	-0.17	Inst Own	42.63%	Short Float	13.09%	Perf Quarter	17.24%
Income	-54.24M	P/S	6.23	EPS this Y	-37.04%	Inst Trans	1.26%	Short Ratio	7.81	Perf Half Y	-7.10%
Sales	54.23M	P/B	-	EPS next Y	15.22%	ROA	-46.81%	Short Interest	12.00M	Perf YTD	-4.49%
Book/sh	-0.61	P/C	4.92	EPS next 5Y	20.57%	ROE	-	52W High	5.80 -41.38%	Perf Year	31.27%
Cash/sh	0.69	P/FCF	-	EPS past 3/5Y	34.99% 27.90%	ROIC	-87.52%	52W Low	2.12 60.38%	Perf 3Y	359.46%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	4.23% 1.82%	Gross Margin	68.40%	Volatility	5.12% 7.68%	Perf 5Y	-35.36%
Dividend TTM	-	EV/Sales	7.26	EPS Y/Y TTM	-37.31%	Oper. Margin	-75.94%	ATR (14)	0.22	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.48	Sales Y/Y TTM	5.29%	Profit Margin	-100.02%	RSI (14)	59.58	Recom	1.11
Dividend Gr. 3/5Y	- -	Current Ratio	4.87	EPS Q/Q	-37.75%	SMA20	0.77%	Beta	1.97	Target Price	8.42
Payout	-	Debt/Eq	-	Sales Q/Q	-27.65%	SMA50	15.49%	Rel Volume	0.70	Prev Close	3.31
Employees	142	LT Debt/Eq	-	Earnings	May 12 AMC	SMA200	-5.80%	Avg Volume	1.54M	Price	3.40
IPO	Jul 25, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-45.45% -28.70%	Trades		Volume	1,074,054	Change	2.72%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-02-25	Resumed	Oppenheimer	Outperform	$7
Dec-17-24	Initiated	Cantor Fitzgerald	Overweight	$17
May-10-24	Initiated	Leerink Partners	Outperform	$8
Apr-11-24	Initiated	Piper Sandler	Overweight	$10
Mar-28-24	Initiated	Raymond James	Outperform	$7
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$7
Apr-22-19	Initiated	H.C. Wainwright	Buy
Jan-03-19	Initiated	Lake Street	Buy	$14
Aug-20-18	Initiated	RBC Capital Mkts	Outperform	$23
Aug-20-18	Initiated	JMP Securities	Mkt Outperform	$29

Jun-25-25 07:00AM	Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit (GlobeNewswire)
Jun-24-25 08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Jun-16-25 07:00AM	Aquestive Therapeutics Announces FDA Acceptance of New Drug Application and PDUFA Date for Anaphylm for the Treatment of Severe Allergic Reactions (GlobeNewswire)
May-21-25 11:17AM	Aquestive Therapeutics, Inc. (AQST): Analysts See 245% Upside Potential (Insider Monkey) -5.02%
May-14-25 03:05AM	Aquestive Therapeutics Inc (AQST) Q1 2025 Earnings Call Highlights: Navigating Revenue Declines ... (GuruFocus.com)
05:30PM	Loading…
May-12-25 05:30PM	Aquestive Therapeutics (AQST) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks) -19.65%
05:15PM	Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:08PM	Aquestive Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
09:38AM	Earnings To Watch: Aquestive Therapeutics Inc (AQST) Reports Q1 2025 Result (GuruFocus.com)
May-09-25 09:40AM	Aquestive Therapeutics Inc (AQST) Q1 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
May-08-25 05:15PM	Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Surpass Estimates (Zacks)
May-05-25 07:00AM	Aquestive Therapeutics to Participate in Citizens Life Sciences Conference (GlobeNewswire) -5.67%
May-04-25 04:32PM	Aquestive Therapeutics: Unprofitable For A Few More Years, But Significant Upside Potential (Seeking Alpha)
May-01-25 07:00AM	Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET (GlobeNewswire)
09:09AM	Loading…
Apr-14-25 09:09AM	Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength? (Zacks)
Apr-09-25 07:00AM	Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium (GlobeNewswire) +8.86%
Apr-01-25 07:00AM	Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm (epinephrine) Sublingual Film (GlobeNewswire)
Mar-25-25 08:35AM	Aquestive Therapeutics: Oral Anaphylaxis NDA Opportunity Spells Buy (SeekingAlpha)
Mar-24-25 05:37AM	Aquestive Therapeutics: Not For Me, But Attractive (SeekingAlpha)
Mar-07-25 02:07AM	Aquestive Therapeutics Inc (AQST) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Mar-05-25 06:30PM	Compared to Estimates, Aquestive Therapeutics (AQST) Q4 Earnings: A Look at Key Metrics (Zacks) -7.53%
05:10PM	Aquestive Therapeutics (AQST) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:18PM	Aquestive Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
07:26AM	What To Expect From Aquestive Therapeutics Inc (AQST) Q4 2024 Earnings (GuruFocus.com)
Mar-04-25 07:21AM	Aquestive Therapeutics Inc (AQST) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-26-25 07:00AM	Aquestive Therapeutics to Participate in Two Upcoming Conferences in March (GlobeNewswire)
Feb-20-25 07:00AM	Aquestive Therapeutics to Report Fourth Quarter 2024 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET (GlobeNewswire)
Feb-12-25 07:00AM	Aquestive Therapeutics to Present New Findings on Anaphylm (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting (GlobeNewswire) +14.14%
07:00AM	Loading…
Feb-04-25 07:00AM	Aquestive Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Conference (GlobeNewswire) +6.23%
Jan-13-25 07:00AM	Aquestive Therapeutics Provides Business Update and Outlines Key 2025 Objectives (GlobeNewswire)
Dec-19-24 11:40AM	Aquestive Therapeutics Gains FDA Orphan Drug Exclusivity for Pediatric Seizure Treatment (GuruFocus.com) +5.20%
08:00AM	Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five (GlobeNewswire)
Dec-17-24 01:56PM	Developer Of EpiPen Alternative Aquestive Stock Undervalued Despite Strong Clinical Data, Analyst Sees Huge Upside (Benzinga) +6.94%
Dec-02-24 08:00AM	Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm (epinephrine) Sublingual Film (GlobeNewswire) -5.50%
Nov-16-24 01:25AM	Is Aquestive Therapeutics (AQST) the Best Multibagger Stock to Buy Heading into 2025? (Insider Monkey)
Nov-12-24 08:00AM	Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Nov-06-24 02:07AM	Aquestive Therapeutics Inc (AQST) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ... (GuruFocus.com) +6.62%
Nov-04-24 07:00PM	Aquestive Therapeutics (AQST) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks) -6.70% -7.67%
05:50PM	Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:48PM	Aquestive Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:36PM	Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
07:11AM	Aquestive Therapeutics Inc (AQST) Q3 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Nov-01-24 09:07AM	Aquestive Therapeutics Inc (AQST) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Oct-25-24 08:29AM	Aquestive Therapeutics Breakthrough in Allergy Treatment Study (TipRanks)
08:00AM	Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm (epinephrine) Sublingual Film Demonstrating Comparable PK and PD Data to Epinephrine Injection Regardless of Variable Placement or Intraoral Movement at American College of Allergy Asthma and Immunology (ACAAI) 2024 Annual Meeting (GlobeNewswire)
Oct-24-24 08:00AM	Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm (epinephrine) Sublingual Film (GlobeNewswire)
Oct-21-24 08:00AM	Aquestive Therapeutics to Report Third Quarter 2024 Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET (GlobeNewswire)
Sep-30-24 02:25PM	Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate (Benzinga) +5.51%
Sep-27-24 08:30AM	Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day (GlobeNewswire) -5.60%
Sep-09-24 08:15AM	Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th (GlobeNewswire) +12.20%
Aug-22-24 08:00AM	Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire) -7.31%
Aug-14-24 08:00AM	Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm (GlobeNewswire)
Aug-06-24 06:30PM	Aquestive Therapeutics (AQST) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:35PM	Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:32PM	Aquestive Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:22PM	Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-25-24 08:00AM	Aquestive Therapeutics Reports Positive Topline Data for Anaphylm (epinephrine) Sublingual Film from Self-Administration Study (GlobeNewswire)
Jul-23-24 08:00AM	Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET (GlobeNewswire) +9.90%
Jun-27-24 08:00AM	Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism (GlobeNewswire) +7.02%
Jun-25-24 01:00PM	Oral Allergy Medication For Emergencies - Aquestive Therapeutics' Investigational Therapy Works Even With Exposure To Liquids Of Different Temperatures, Data Shows (Benzinga)
08:00AM	Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm (epinephrine) Sublingual Film (GlobeNewswire)
Jun-18-24 08:00AM	Aquestive Therapeutics to Join the Russell 3000 and Russell 2000 Indexes Effective June 28, 2024 (GlobeNewswire)
Jun-03-24 08:00AM	Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities (GlobeNewswire)
May-28-24 08:00AM	Aquestive Therapeutics to Present Anaphylm (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy Conference (GlobeNewswire)
May-10-24 07:11AM	Leerink Partners Starts Aquestive Therapeutics With Outperform Rating, $8 Price Target (MT Newswires) -6.08%
May-09-24 04:51PM	Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2024 Earnings Call Transcript (Insider Monkey) +6.65%
08:00AM	Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference (GlobeNewswire)
03:05AM	Aquestive Therapeutics Inc (AQST) Q1 2024 Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)
May-07-24 09:57PM	AQST Stock Earnings: Aquestive Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) -8.73%
07:00PM	Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics (Zacks)
05:25PM	Aquestive Therapeutics (AQST) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:29PM	Aquestive Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:19PM	Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-30-24 10:01AM	Analysts Estimate Aquestive Therapeutics (AQST) to Report a Decline in Earnings: What to Look Out for (Zacks) -10.04%
Apr-29-24 11:19AM	Aquestive Therapeutics Obtains FDA Approval for Libervant to Treat Seizure in Children (MT Newswires) -8.23%
07:00AM	Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm (epinephrine) Sublingual Film (GlobeNewswire)
Apr-25-24 08:00AM	Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET (GlobeNewswire)
Apr-17-24 08:00AM	Coming FDA Approvals Could Send These 3 Drug Stocks Soaring (InvestorPlace)
Apr-12-24 04:01PM	Aquestive Therapeutics to Present Crossover Study Data for Libervant (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology (GlobeNewswire)
Apr-02-24 06:15PM	Aquestive Therapeutics (AQST) Ascends While Market Falls: Some Facts to Note (Zacks) +5.80%
Apr-01-24 08:00AM	Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive (GlobeNewswire)
Mar-25-24 08:00AM	Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock (GlobeNewswire)
Mar-22-24 06:00PM	Aquestive Therapeutics (AQST) Flat As Market Sinks: What You Should Know (Zacks)
Mar-20-24 08:46AM	Why Is Aquestive Therapeutics (AQST) Stock Down 14% Today? (InvestorPlace) -15.64%
Mar-19-24 09:49PM	Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock (GlobeNewswire)
05:00PM	Insider Sell: Chief Innovation/Tech Officer Alexander Schobel Sells 50,000 Shares of Aquestive ... (GuruFocus.com)
04:01PM	Aquestive Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Mar-18-24 11:47AM	Aquestive (AQST) Up as Anaphylm Pivotal Study Meets Goals (Zacks) -9.52%
06:46AM	Strength Seen in Aquestive Therapeutics (AQST): Can Its 16.0% Jump Turn into More Strength? (Zacks)
Mar-15-24 01:00PM	5 Growth Stocks Under $50 for March 2024 (Investopedia) +16.00%
Mar-14-24 05:23PM	Aquestive Therapeutics Announces Pivotal Study for Anaphylm (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting (GlobeNewswire)
Mar-12-24 05:00PM	Insider Sell: Chief Innovation/Tech Officer Alexander Schobel Sells 25,000 Shares of Aquestive ... (GuruFocus.com) +6.67%
Mar-07-24 01:43PM	Aquestive Therapeutics Inc Reports Full Year 2023 Financial Results (GuruFocus.com) +12.92%
11:56AM	Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2023 Earnings Call Transcript (Insider Monkey)
12:53AM	Q4 2023 Aquestive Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-05-24 10:51PM	AQST Stock Earnings: Aquestive Therapeutics Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) +20.05%
06:15PM	Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
05:15PM	Aquestive Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients' therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jung Cassie	Chief Operating Officer	Nov 26 '24	Sale	4.87	44	214	0	Nov 27 04:24 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Aquestive Therapeutics Inc

Upgrade your FINVIZ experience